Hooman Kamel, MD
Weill Cornell Medical College
Dr. Kamel is Chief of the Division of Neurocritical Care and Director of the Clinical and Translational Neuroscience Unit in the Department of Neurology and the Feil Family Brain and Mind Research Institute at Weill Cornell Medicine. His research focuses on the relationship between cardiac disease and stroke. He has published several studies showing that atrial cardiopathy may be a previously unrecognized risk factor for stroke. He is a principal investigator and protocol lead for the NIH-funded ARCADIA trial, which is testing antithrombotic strategies in patients with stroke and atrial cardiopathy. He is also a principal investigator of the NIH-funded ASPIRE trial, which is testing antithrombotic strategies in patients with atrial fibrillation and intracerebral hemorrhage. He has published over 275 scientific publications, including in leading journals such as NEJM and JAMA.
Dr. Kamel attended college at Harvard and medical school at Columbia, then trained as a neurology resident and neurocritical care fellow at the University of California, San Francisco. He has a masters degree in data science from the Columbia University Data Science Institute. He serves as the Deputy Editor of JAMA Neurology and an editorial board member of Stroke. His academic contributions have been recognized by the Michael S. Pessin Stroke Leadership Prize from the American Academy of Neurology and the Robert G. Siekert New Investigator Award in Stroke from the American Heart Association.